Also Read | Covid far from over in some statesWe won’t know the efficacy of the vaccine for another couple of weeks — that’s when the first results from late-stage, phase III trials will be reported — but the data from an earlier stage in the trial that was just published in a peer-reviewed article in the New England Journal of Medicine helps us make some predictions.
The findings, looking at various aspects of the immune response after one or two doses, look better than the preliminary report from the same trial that we saw in September.
After just one dose, the immune reaction looks similar to that seen with two doses of the Pfizer Inc.-BioNTech SE and Moderna Inc.